<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26442/2075082X.2021.4.201299</article-id><article-id custom-type="elpub" pub-id-type="custom">systhiper-667</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Предикторы сердечно-сосудистых осложнений у больных артериальной гипертензией и коморбидной патологией</article-title><trans-title-group xml:lang="en"><trans-title>Predictors of cardiovascular complications in patients with arterial hypertension and comorbid pathology</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8513-9279</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муркамилов</surname><given-names>И. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Murkamilov</surname><given-names>I. T.</given-names></name></name-alternatives><email xlink:type="simple">murkamilov.i@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2682-4417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomin</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">murkamilov.i@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0632-6653</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юсупов</surname><given-names>Ф. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yusupov</surname><given-names>F. A.</given-names></name></name-alternatives><email xlink:type="simple">murkamilov.i@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8387-5800</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сабиров</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sabirov</surname><given-names>I. S.</given-names></name></name-alternatives><email xlink:type="simple">murkamilov.i@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кыргызская государственная медицинская академия им. И.К. Ахунбаева; ГОУ ВПО «Кыргызско-Российский Славянский университет им. первого Президента Российской Федерации Б.Н. Ельцина»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Akhunbaev Kyrgyz State Medical Academy; Yeltsin Kyrgyz Russian Slavic University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Ошский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Osh State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ГОУ ВПО «Кыргызско-Российский Славянский университет им. первого Президента Российской Федерации Б.Н. Ельцина»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yeltsin Kyrgyz Russian Slavic University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>06</day><month>02</month><year>2023</year></pub-date><volume>18</volume><issue>4</issue><fpage>180</fpage><lpage>185</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Муркамилов И.Т., Фомин В.В., Юсупов Ф.А., Сабиров И.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Муркамилов И.Т., Фомин В.В., Юсупов Ф.А., Сабиров И.С.</copyright-holder><copyright-holder xml:lang="en">Murkamilov I.T., Fomin V.V., Yusupov F.A., Sabirov I.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/667">https://www.syst-hypertension.ru/jour/article/view/667</self-uri><abstract><p>Цель. Изучить взаимосвязь центрального артериального давления (АД) и цистатина С у больных артериальной гипертензией (АГ) и коморбидной патологией в зависимости от гендерных различий. Материалы и методы. Обследованы 162 больных в возрасте от 39 до 82 лет, страдающих АГ и коморбидной патологией. Средний возраст обследованных составил 58,6±10,3 года. Выявлены следующие нозологические формы: коронарная болезнь сердца - 40,7% обследованных, избыточная масса тела - 33,9%, ожирение 1-й степени - 30,8%, сахарный диабет 2-го типа - 29,0%, хроническая обструктивная болезнь легких - 16,6%, цереброваскулярные заболевания - 13,5%. Всем участникам проводились общеклинические обследования. Исследовали концентрации липидного спектра: уровни общего холестерина, триглицеридов, холестерина (ХС) липопротеинов высокой плотности - ХС ЛПВП и ХС липопротеинов низкой плотности (ХС ЛПНП) и цистатина С плазмы крови. Скорость клубочковой фильтрации (СКФ) рассчитывалась по формуле F. Hoek (80,35/цистатин С - 4,32=СКФ). Исследование центрального аортального давления (ЦАД), мм рт. ст., проводилось при помощью прибора «АнгиоСкан». Эхокардиография выполнялась на аппарате «Vivid q» (США, 2014 г.) по общепринятой методике. Все обследованные больные разделены на 2 подгруппы. В 1-ю подгруппу включены женщины, во 2-ю - мужчины. Результаты. У больных АГ и коморбидной патологией наиболее распространенными отклонениями оказались повышенный уровень ХС ЛПНП (58%), пониженный уровень ХС ЛПВП (51,8%), гиперхолестеринемия (54,3%), гипертриглицеридемия (43,8%) и тахикардия (40,7%). У 51,8% обследованных, причем больше среди лиц мужского пола, выявлялось достижение целевого уровня АД. У женщин показатели среднего возраста, индекса массы тела, содержания общего ХС, ХС ЛПНП и ХС ЛПВП были значимо выше. У больных мужского пола показатели диаметра выходного тракта аорты, конечного систолического и диастолического размеров левого желудочка (ЛЖ) значимо превышали аналогичные показатели у женщин, а фракция выброса ЛЖ была существенно ниже. Распространенность гипертрофии ЛЖ (ГЛЖ) составила в общей выборке 37%, причем у женщин была выше, чем у мужчин (45,9 и 26,6% соответственно, p=0,012). При этом частоты концентрического и эксцентрического типов ГЛЖ в обеих подруппах оказались схожи. Частота встречаемости концентрического ремоделирования ЛЖ у женщин и мужчин составляла 5,7 и 13,3% соответственно (p=0,001). В обеих подгруппах выявлена отрицательная корреляция между индексом массы миокарда ЛЖ и величиной расчетной СКФ. Положительная корреляция отмечена между уровнями систолического АД и ЦАД, концентрациями цистатина С и триглицеридов плазмы крови. Заключение. При АГ в структуре коморбидной патологии преобладают коронарная болезнь сердца, ожирение и сахарный диабет 2-го типа, когда часто выявлялись гипер- и дислипидемия. Частота встречаемости ГЛЖ в общей группе обследуемых составляла 37,0%, причем у женщин этот показатель был выше. В подгруппе мужчин значимо чаще выявлялись случаи концентрического ремоделирования ЛЖ. Рост уровня ЦАД и систолического АД, а также концентрации цистатина С ассоциировался с увеличением индекса массы миокарда ЛЖ, особенно в подгруппе женщин.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To study the relationship between central arterial pressure (BP) and cystatin C in patients with arterial hypertension and comorbid pathology, depending on gender differences. Materials and methods. The study involved 162 patients aged 39 to 82 years, suffering from hypertension and comorbid pathology. The average age of the surveyed was 58.6±10.3 years. The following nosological forms were revealed: coronary heart disease - 40.7% of the examined, overweight - 33.9%, 1st degree obesity - 30.8%, type 2 diabetes mellitus - 29.0%, chronic obstructive disease lungs - 16.6%, cerebrovascular diseases - 13.5%. All participants underwent general clinical examinations. The concentration of the lipid spectrum was investigated: the levels of total cholesterol, triglycerides, cholesterol high density lipoproteins (HDL cholesterol) and low density lipoprotein cholesterol (LDL cholesterol) and plasma cystatin C. Glomerular filtration rate (GFR) was calculated according to F. Hoek's formula (80.35/cystatin C - 4.32=GFR). Study of central aortic pressure (CAP), mm Hg Art., was carried out using the device "AngioScan". Echocardiography was performed on a "Vivid q" apparatus (USA, 2014) according to the generally accepted technique. All examined patients were divided into 2 subgroups. The 1st subgroup includes women, the 2nd - men. Results. In patients with hypertension and comorbid pathology, the most common abnormalities were an increased level of LDL cholesterol (58%), a decreased level of HDL cholesterol (51.8%), hypercholesterolemia (54.3%), hypertriglyceridemia (43.8%) and tachycardia (40.7%). In 51.8% of the surveyed, and more among males, the achievement of the target blood pressure level was detected. In women, the indicators of average age, body mass index, the content of total cholesterol, LDL cholesterol and HDL cholesterol were significantly higher. In male patients, the indicators of the diameter of the aortic outflow tract, end systolic and diastolic dimensions of the left ventricle (LV) significantly exceeded those of women, and the ejection fraction of the LV was significantly lower. The prevalence of LV hypertrophy (LVH) was 37% in the total sample, and it was higher in women than in men (45.9 and 26.6%, respectively, p=0.012). At the same time, the frequencies of concentric and eccentric types of LVH in both subgroups were similar. The incidence of LV concentric remodeling in women and men was 5.7 and 13.3%, respectively (p=0.001). In both subgroups, a negative correlation was found between the LV myocardial mass index and the calculated GFR. A positive correlation was noted between the levels of systolic blood pressure and CAP, the concentrations of cystatin C and plasma triglycerides. Conclusion. In hypertension, the structure of comorbid pathology is dominated by coronary heart disease, obesity and type 2 diabetes mellitus, when hyper- and dyslipidemia were often detected. The incidence of LVH in the general group of subjects was 37.0%, and in women this indicator was higher. In the subgroup of men, cases of LV concentric remodeling were significantly more frequent. An increase in the level of CAP and systolic blood pressure, as well as the concentration of cystatin C, was associated with an increase in the LV myocardial mass index, especially in the subgroup of women.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>коморбидная патология</kwd><kwd>цистатин С</kwd><kwd>сердечно-сосудистые осложнения</kwd><kwd>гендерные различия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>comorbid pathology</kwd><kwd>cystatin C</kwd><kwd>cardiovascular complications</kwd><kwd>gender differences</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Аксенова А.В., Ощепкова Е.В. Особенности течения артериальной гипертонии у мужчин и женщин (по данным Национального регистра артериальной гипертонии). Терапевтический архив. 2019;91(1):4-12 DOI:10.26442/00403660.2019.01.000021</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Aksenova AV, Oschepkova EV. Clinical features of arterial hypertension in men and women (according to the National Registry of Arterial Hypertension). Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(1):4-12 (in Russian). doi: 10.26442/00403660.2019.01.000021</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S, Shankar R, Singh GP. Prevalence and associated risk factors of hypertension: a cross-sectional study in urban Varanasi. Int J Hypertens. 2017;2017:5491838. DOI:10.1155/2017/5491838</mixed-citation><mixed-citation xml:lang="en">Singh S, Shankar R, Singh GP. Prevalence and associated risk factors of hypertension: a cross-sectional study in urban Varanasi. Int J Hypertens. 2017;2017:5491838. doi: 10.1155/2017/5491838</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ezzati M, Oza S, Danaei G, Murray CJL. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation. 2008;117(7):905-14. DOI:10.1161/circulationaha.107.732131</mixed-citation><mixed-citation xml:lang="en">Ezzati M, Oza S, Danaei G, Murray CJL. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation. 2008;117(7):905-14. doi: 10.1161/circulationaha.107.732131</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 DOI:10.26442/2075082X.2019.1.190179</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Zhernakova YV. Diagnosis and treatment of arterial hypertension [Guidelines]. Systemic Hypertension. 2019;16(1):6-31 (in Russian). doi: 10.26442/2075082X.2019.1.190179</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressurerelated disease, 2001. Lancet. 2008;371(9623):1513-18. DOI:10.1016/s0140-6736(08)60655-8</mixed-citation><mixed-citation xml:lang="en">Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressurerelated disease, 2001. Lancet. 2008;371(9623):1513-18. doi: 10.1016/s0140-6736(08)60655-8</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Чесникова А.И., Батюшин М.М., Терентьев В.П. Артериальная гипертензия и коморбидность: современное состояние проблемы. Артериальная гипертензия. 2016;22(5):432-40 DOI:10.18705/1607-419X-2016-22-5-432-440</mixed-citation><mixed-citation xml:lang="en">Chesnikova AI, Batyushin MM, Terentyev VP. Arterial hypertension and comorbidity: state of the art. Arterial Hypertension. 2016;22(5):432-40 (in Russian). doi: 10.18705/1607-419X-2016-22-5-432-440</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В. Рекомендации по диагностике и лечению артериальной гипертонии 2018 г. - слово за европейскими экспертами. Системные гипертензии. 2018;15(3):6-10 DOI:10.26442/2075-082_2018.3</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Zhernakova YuV. Guidelines for diagnostics and treatment of hypertension 2018 – European experts’ opinion. Systemic Hypertension. 2018;15(3):6-10 (in Russian). doi: 10.26442/2075-082_2018.3</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18(10):2024-31. DOI:10.1093/ndt/gfg349</mixed-citation><mixed-citation xml:lang="en">Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18(10):2024-31. doi: 10.1093/ndt/gfg349</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79-108. DOI:10.1016/j.euje.2005.12.014</mixed-citation><mixed-citation xml:lang="en">Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79-108. doi: 10.1016/j.euje.2005.12.014</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613-8. PMID:138494.</mixed-citation><mixed-citation xml:lang="en">Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613-8. PMID: 138494.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. DOI:10.1097/HJH.0000000000001940</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. doi: 10.1097/HJH.0000000000001940</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915-26. DOI:10.1016/S1474-4422(08)70193-5</mixed-citation><mixed-citation xml:lang="en">Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915-26. doi: 10.1016/S1474-4422(08)70193-5</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто Е.В., Конради А.О. Структурно-функциональные изменения миокарда у больных гипертонической болезнью. Кардиология. 1999;2:49-55</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, Konradi AO. Strukturno-funktsional'nye izmeneniia miokarda u bol'nykh gipertonicheskoi bolezn'iu. Kardiologiia.1999;2:49-55 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Российский кардиологический журнал. 2018;12:131-42 DOI:10.15829/1560-4071-2018-12-131-142</mixed-citation><mixed-citation xml:lang="en">Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;12:131-42 (in Russian). doi: 10.15829/1560-4071-2018-12-131-142</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rabahi MF, Pereira SA, Silva Junior JL, et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10(1):1525-9. DOI:10.2147/COPD.S85588</mixed-citation><mixed-citation xml:lang="en">Rabahi MF, Pereira SA, Silva Junior JL, et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10(1):1525-9. doi: 10.2147/COPD.S85588</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95-109. DOI:10.2147/COPD.S54473</mixed-citation><mixed-citation xml:lang="en">Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95-109. doi: 10.2147/COPD.S54473</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Portegies ML, Lahousse L, Joos GF, et al. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam study. Am J Respir Crit Care Med. 2015;193(3):251-8. DOI:10.1164/rccm.201505-0962OC</mixed-citation><mixed-citation xml:lang="en">Portegies ML, Lahousse L, Joos GF, et al. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam study. Am J Respir Crit Care Med. 2015;193(3):251-8. doi: 10.1164/rccm.201505-0962OC</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Кисляк О.А., Мышляева Т.О., Малышева Н.В. Сахарный диабет 2 типа, артериальная гипертензия и риск сердечно-сосудистых осложнений. Сахарный диабет. 2008;1:45-9</mixed-citation><mixed-citation xml:lang="en">Kislyak OA, Myshlyaeva TO, Malysheva NV, et al. Type 2 diabetes, hypertension and the risk of cardiovascular complications. Diabetes Mellitus. 2008;1:45-9 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Derakhshan A, Bagherzadeh-Khiabani F, Arshi B, et al. Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. J Am Heart Assoc. 2016;5(8):e003917. DOI:10.1161/JAHA.116.003917</mixed-citation><mixed-citation xml:lang="en">Derakhshan A, Bagherzadeh-Khiabani F, Arshi B, et al. Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. J Am Heart Assoc. 2016;5(8):e003917. doi: 10.1161/JAHA.116.003917</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-9. DOI:10.1001/jama.295.2.180</mixed-citation><mixed-citation xml:lang="en">Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-9. doi: 10.1001/jama.295.2.180</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol. 2004;43(4):576-82. DOI:10.1016/j.jacc.2003.10.031</mixed-citation><mixed-citation xml:lang="en">Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol. 2004;43(4):576-82. doi: 10.1016/j.jacc.2003.10.031</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27(16):1979-2030. DOI:10.1093/eurheartj/ehl176</mixed-citation><mixed-citation xml:lang="en">Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27(16):1979-2030. doi: 10.1093/eurheartj/ehl176</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;8:7-13 DOI:10.15829/1560-4071-2016-8-7-13</mixed-citation><mixed-citation xml:lang="en">Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;8:7-13 (in Russian). doi: 10.15829/1560-4071-2016-8-7-13</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Devereux RB, Pickering TG, Alderman MH, et al. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension. 1987;9(2 Pt. 2):II53-60. DOI:10.1161/01.hyp.9.2_pt_2.ii53</mixed-citation><mixed-citation xml:lang="en">Devereux RB, Pickering TG, Alderman MH, et al. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension. 1987;9(2 Pt. 2):II53-60. doi: 10.1161/01.hyp.9.2_pt_2.ii53</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Малютина С.К., Рябиков А.Н., Шахматов С.Г., и др. Артериальная гипертензия и поражение органов-мишеней: прогностическое значение гипертрофии миокарда в сибирской популяции. Бюллетень Сибирского отделения Российской академии медицинских наук. 2001;5(31):53-8</mixed-citation><mixed-citation xml:lang="en">Malyutina SK, Ryabikov AN, Shakhmatov SG, et al. Arterial hypertension and target organs damage: prognostic significance of myocardium hypertrophy in siberian population. The Bulletin of Siberian Branch of Russian Academy of Medical Sciences. 2001;5(31):53-8 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Gerdts E, Izzo R, Mancusi C, et al. Left ventricular hypertrophy offsets the sex difference in cardiovascular risk (the Campania Salute Network). Int J Cardiol. 2018;258:257-61. DOI:10.1016/j.ijcard.2017.12.086</mixed-citation><mixed-citation xml:lang="en">Gerdts E, Izzo R, Mancusi C, et al. Left ventricular hypertrophy offsets the sex difference in cardiovascular risk (the Campania Salute Network). Int J Cardiol. 2018;258:257-61. doi: 10.1016/j.ijcard.2017.12.086</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Levy D, Anderson K, Savage D, et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol. 1987;60(7):560-5. DOI:10.1016/0002-9149(87)90305-5</mixed-citation><mixed-citation xml:lang="en">Levy D, Anderson K, Savage D, et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol. 1987;60(7):560-5. doi: 10.1016/0002-9149(87)90305-5</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Муркамилов И.Т., Фомин В.В., Айтбаев К.А., и др. Содержание цистатина С плазмы крови и его взаимо- связь с аугментационным индексом и центральным артериальным давлением у пациентов терапевтического профиля. Клиническая нефрология. 2018;3:31-40 DOI:10.18565/nephrology.20183.31-40</mixed-citation><mixed-citation xml:lang="en">Murkamilov IT, Fomin VV, Aitbaev KA, et al. Blood plasma cystatin С level and its relationship with the augmentation index and central arterial pressure in therapeutic patients. Clin Nephrol. 2018;3:31-40 (in Russian). doi: 10.18565/nephrology.20183.31-40</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Муркамилов И.Т., Сабиров И.С., Фомин В.В., и др. Оценка нефроцеребрального риска с использованием цистатина С у больных хронической болезнью почек. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(9):10-6 DOI:10.17116/jnevro201811809110</mixed-citation><mixed-citation xml:lang="en">Murkamilov IT, Sabirov IS, Fomin VV, et al. Evaluation of nephrocerebral risk using cystatin C in patients with chronic kidney disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(9):10-6 (in Russian). doi: 10.17116/jnevro201811809110</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Муркамилов И.Т., Сабиров И.С., Айтбаев К.А., и др. Почечная дисфункция и показатели артериальной жесткости у лиц пожилого и старческого возраста. Успехи геронтологии. 2018;31(4):549-55</mixed-citation><mixed-citation xml:lang="en">Murkamilov IT, Sabirov IS, Aitbaev KA, et al. Renal dysfunction and indicators of arterial hormity in persons of elderly and senile age. Advances in Gerontology. 2018;31(4):549-55 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Руденко Т.Е., Васильева М.П., Кутырина И.М., Соломахина Н.И. Сывороточная концентрация цистатина С и мочевой кислоты у пациентов с хронической болезнью почек и гипертрофией левого желудочка сердца. Нефрология. 2015;19(2):68-75</mixed-citation><mixed-citation xml:lang="en">Rudenko TE, Vasilyeva MP, Kutyrina IM, Solomakhina NI. Cystatin C and uric acid levels in detecting left ventricular hypertrophy in patients with chronic kidney disease. Nephrology (Saint Petersburg). 2015;19(2):68-75 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Taglieri N, Koenig W, Kaski JC. Cystatin C and Cardiovascular Risk. Clin Chem. 2009;55(11):1932-43. DOI:10.1373/clinchem.2009.128397</mixed-citation><mixed-citation xml:lang="en">Taglieri N, Koenig W, Kaski JC. Cystatin C and Cardiovascular Risk. Clin Chem. 2009;55(11):1932-43. doi: 10.1373/clinchem.2009.128397</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Reese PP, Feldman HI. More evidence that cystatin C predicts mortality better than creatinine. J Am Soc Nephrol. 2009;20(10):2085-92. DOI:10.1681/ASN.2009080832</mixed-citation><mixed-citation xml:lang="en">Reese PP, Feldman HI. More evidence that cystatin C predicts mortality better than creatinine. J Am Soc Nephrol. 2009;20(10):2085-92. doi: 10.1681/ASN.2009080832</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Chung YK, Lee YJ, Kim KW, et al. Serum cystatin C is associated with subclinical atherosclerosis in patients with type 2 diabetes: a retrospective study. Diab Vasc Dis Res. 2018;15(1):24-30. DOI:10.1177/1479164117738156</mixed-citation><mixed-citation xml:lang="en">Chung YK, Lee YJ, Kim KW, et al. Serum cystatin C is associated with subclinical atherosclerosis in patients with type 2 diabetes: a retrospective study. Diab Vasc Dis Res. 2018;15(1):24-30. doi: 10.1177/1479164117738156</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
